SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wanbury strengthens Coriminic brand with launch of Coriminic CPM Drops

24 Mar 2026 Evaluate

Wanbury has further strengthened its well-known brand - Coriminic, for children cold & sneezing usage, with launch of Coriminic CPM Drops (Chlorpheniramine Maleate) without combination of decongestant for pediatric/ children usage, to address the drug control notification restricting fixed-dose cold combinations in children under 4 years of age.

Alongside Corirninic CPM Drops, Wanbury is strengthening the Corirninic brand with Coriminic NS (Normal Saline) Nasal Drops, a non-systemic nasal decongestant solution designed to provide localised relief for children from nasal congestion, helping physicians navigate treatment options within government regulatory boundaries.

This launch comes in the context of recent advisories and regulatory restrictions issued by the Drugs Controller General of India (DCGI), which have limited the use of fixed-dose combinations, those containing Chlorpheniramine + Phenylephrine, in children below 4 years due to safety concerns.

This strategic move positions Wanbury to capture a significant share of the Rs 861 crore Cold Preparation Liquid market and navigate the restrictions laid by DCGI. With this expansion, Wanbury is poised to further consolidate its presence in the fast-growing children Cold Preparation Liquid market.  

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

Wanbury Share Price

259.05 -6.90 (-2.59%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×